AstraZeneca (LON:AZN) Earns “Buy” Rating from Berenberg Bank

AstraZeneca (LON:AZN)‘s stock had its “buy” rating reissued by analysts at Berenberg Bank in a note issued to investors on Monday, Marketbeat.com reports. They presently have a GBX 140 ($1.75) price objective on the biopharmaceutical company’s stock. Berenberg Bank’s target price would indicate a potential downside of 98.69% from the stock’s current price.

A number of other research analysts have also weighed in on the stock. Shore Capital reissued a “buy” rating on shares of AstraZeneca in a report on Thursday, November 7th. JPMorgan Chase & Co. reissued an “overweight” rating and issued a £140 ($174.65) price objective on shares of AstraZeneca in a research note on Friday, November 22nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of GBX 7,935.67 ($99.00).

AstraZeneca Stock Performance

LON AZN opened at £106.68 ($133.08) on Monday. The company has a debt-to-equity ratio of 84.97, a current ratio of 0.89 and a quick ratio of 0.59. AstraZeneca has a 1-year low of GBX 9,461 ($118.03) and a 1-year high of £133.88 ($167.02). The business has a 50 day simple moving average of £105.13 and a two-hundred day simple moving average of £116.82. The stock has a market capitalization of £165.35 billion, a PE ratio of 3,386.67, a P/E/G ratio of 0.86 and a beta of 0.17.

Insider Transactions at AstraZeneca

In related news, insider Pascal Soriot bought 20,000 shares of the business’s stock in a transaction on Thursday, November 14th. The shares were bought at an average price of £102.03 ($127.28) per share, for a total transaction of £2,040,600 ($2,545,658.68). Also, insider Tony Mok purchased 1,500 shares of the firm’s stock in a transaction on Tuesday, November 19th. The shares were purchased at an average cost of £126.80 ($158.18) per share, with a total value of £190,200 ($237,275.45). Corporate insiders own 0.04% of the company’s stock.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.